PIRS Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 6.39%
Insider Buying (Last 12 Months): $92,311.00
Insider Selling (Last 12 Months): $0.00

Pieris Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Pieris Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50k$0$50kTotal Insider BuyingTotal Insider Selling

Pieris Pharmaceuticals Share Price & Price History

Current Price: $13.60
Price Change: +0.30 (1.20%)
As of 12/13/2024 01:00 AM ET

This chart shows the closing price history over time for PIRS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Pieris Pharmaceuticals Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Pieris Pharmaceuticals (NASDAQ:PIRS)

40.11% of Pieris Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PIRS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200M-$100M$0$100M$200MTotal InflowsTotal Outflows
Pieris Pharmaceuticals logo
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
Read More on Pieris Pharmaceuticals

Today's Range

Now: $13.60
Low: $13.26
High: $15.35

50 Day Range

MA: $15.17
Low: $13.60
High: $17.07

52 Week Range

Now: $13.60
Low: $6.20
High: $18.68

Volume

51,728 shs

Average Volume

60,946 shs

Market Capitalization

$17.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61

Who are the company insiders with the largest holdings of Pieris Pharmaceuticals?

Pieris Pharmaceuticals' top insider investors include:
  1. Adar1 Capital Management, Llc (Major Shareholder)
  2. Christopher P Kiritsy (Director)
  3. James A Geraghty (Director)
Learn More about top insider investors at Pieris Pharmaceuticals.